MONTREAL, Sept. 17, 2007 (PRIME NEWSWIRE) -- Viropro International Inc., a subsidiary of Viropro Inc. ("Viropro" or the "Company") (OTCBB:VPRO), wishes to update you on the press release dated August 22, 2007. "Both companies agreed on most general clauses, but some articles and technical issues are still to be clarified and agreed on. The final agreement is expected to be signed within the several next days," stated Dr. Jean-Marie Dupuy, CEO of Viropro.
About Intas Biopharmaceuticals Ltd.
IBPL is one of the fastest growing biopharmaceutical companies in India. As an independent entity of Intas group, the company has carved a niche in the biotechnology sector in the country. The company has fully integrated biopharmaceutical operations with an ultra modern R&D facility and an EU-GMP certified Manufacturing Facility approved to manufacture microbial and cell culture derived bulk drugs and finished products in pre-filled syringes and vials (Lyophilized).
About Viropro Inc.
Viropro Inc. conducts operations through its subsidiary Viropro International Inc., whose Head Office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company's principal objective is to provide manufacturing process technology transfers to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. For more information on Viropro Inc., please visit our website at www.viropro.com